- Home
- PL vs ZYME Comparison
PL vs ZYME Comparison
Compare PL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PL
- ZYME
- Stock Information
- Founded
- PL 2010
- ZYME 2003
- Country
- PL United States
- ZYME United States
- Employees
- PL N/A
- ZYME N/A
- Industry
- PL Aerospace
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- PL Industrials
- ZYME Health Care
- Exchange
- PL Nasdaq
- ZYME Nasdaq
- Market Cap
- PL 947.7M
- ZYME 846.1M
- IPO Year
- PL N/A
- ZYME 2017
- Fundamental
- Price
- PL $3.61
- ZYME $11.32
- Analyst Decision
- PL Buy
- ZYME Buy
- Analyst Count
- PL 11
- ZYME 6
- Target Price
- PL $5.53
- ZYME $19.50
- AVG Volume (30 Days)
- PL 3.1M
- ZYME 596.8K
- Earning Date
- PL 06-04-2025
- ZYME 05-08-2025
- Dividend Yield
- PL N/A
- ZYME N/A
- EPS Growth
- PL N/A
- ZYME N/A
- EPS
- PL N/A
- ZYME N/A
- Revenue
- PL $244,352,000.00
- ZYME $76,304,000.00
- Revenue This Year
- PL $14.08
- ZYME $26.29
- Revenue Next Year
- PL $21.49
- ZYME $75.78
- P/E Ratio
- PL N/A
- ZYME N/A
- Revenue Growth
- PL 10.72
- ZYME 0.38
- 52 Week Low
- PL $1.67
- ZYME $8.21
- 52 Week High
- PL $6.71
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- PL 54.32
- ZYME 41.11
- Support Level
- PL $3.38
- ZYME $12.48
- Resistance Level
- PL $3.59
- ZYME $13.23
- Average True Range (ATR)
- PL 0.16
- ZYME 0.55
- MACD
- PL 0.07
- ZYME -0.07
- Stochastic Oscillator
- PL 95.80
- ZYME 18.55
About PL Planet Labs PBC
Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.